Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
We're pleased to be added to multiple Russell Value indexes in 2025 reconstitution, including Russell 2500 Value, Small Cap Value, 2000 Value, Microcap Value & 3000E Value indexes. We also maintained our membership in the Russell 3000 Index.
https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-expands-russell-index-presence-addition
$CADL
More good news: Candel was added to the Russell 2500 Value® Index, Russell Small Cap Value® Index, Russell 2000 Value® Index, Russell Microcap Value® Index, and Russell 3000E® Value Index. Additionally, the Company maintained its membership in the broad-market Russell 3000®…
#ICYMI: @FierceBiotech highlighted our successful phase 3 prostate cancer trial. The study demonstrated a statistically significant 30% reduction in disease recurrence risk
https://www.fiercebiotech.com/biotech/candel-sheds-more-light-sucessful-trial-prostate-cancer-immunotherapy
#ProstateCancer $CADL
Totally agree. Doing what you say you will do is an important trust builder.
People may not always understand the optimal timing of next steps, as they can’t see the whole picture of what management deals with. But they need to be able to trust that management will deliver.
As a CEO, the day to day work and mission (patients, team) is really rewarding and what drives so many of us. With that said, I sometimes see colleagues lose sight of the fact that we need to deliver what we promised to shareholders. What you told them you would do as close as…
